Literature DB >> 22683764

Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation.

Martina M Hughes1, Angela Carballedo, Declan M McLoughlin, Francesco Amico, Andrew Harkin, Thomas Frodl, Thomas J Connor.   

Abstract

The kynurenine pathway (KP) and its rate-limiting tryptophan degrading enzyme indolamine 2,3-dioxygenase (IDO) have been implicated in the pathogenesis of depression. IDO expression is driven by inflammatory cytokines, and has been suggested as the link between inflammation and a serotonergic deficit in depression. Studies also indicate that inflammatory cytokines upregulate the serotonin transporter (SERT), representing another mechanism by which inflammation could influence serotonin availability. Here we examined circulating concentrations of inflammatory cytokines (IFN-γ, TNF-α, IL-1β, IL-6), and the acute phase protein CRP alongside plasma tryptophan, kynurenine, kynurenic acid (KYNA) and 3-hydroxyanthranilic acid (3-HAA) concentrations, and whole blood mRNA expression of IDO, kynurenine aminotransferases (KAT I and II), kynurenine-3-monooxygenase (KMO), kynureninase and SERT in patients with major depressive disorder (MDD) compared with age and sex-matched controls. Whilst no changes in TNF-α or IL-1β were observed, plasma concentrations of IL-6, IFN-γ and CRP were increased in the depressed cohort. Despite this inflammatory phenotype, IDO expression or plasma kynurenine were not significantly different between MDD patients and controls. In addition, there was no difference between controls and depressives in concentrations of KYNA and 3-HAA, or in expression of enzymes KAT, KMO or kynureninase that drive their production. Nonetheless, a depletion in tryptophan was evident in depressed patients and was correlated with HAM-D scores. In addition, we failed to observe any difference in SERT mRNA expression in the blood cells from patients with MDD relative to controls. These data support the idea that a mild inflammatory signature is evident in MDD and is accompanied by reduced circulating tryptophan concentrations. However, we found no indication of KP activation in the depressed cohort suggesting that an alternative mechanism mediates the depletion of tryptophan observed. Taken together these data question the ability of the mild inflammatory phenotype observed in depression to induce molecules such as IDO and SERT that could negatively impact upon serotonergic functioning.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683764     DOI: 10.1016/j.bbi.2012.05.010

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  35 in total

1.  Acute tryptophan depletion reduces nitric oxide synthase in the rat hippocampus.

Authors:  Haipeng Liu; Jian Zhou; Liang Fang; Zhao Liu; Songhua Fan; Peng Xie
Journal:  Neurochem Res       Date:  2013-10-30       Impact factor: 3.996

Review 2.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

3.  Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis.

Authors:  Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne
Journal:  Brain Behav Immun       Date:  2018-06-19       Impact factor: 7.217

4.  The relationship of alcohol use disorders and depressive symptoms to tryptophan metabolism: cross-sectional data from a Nepalese alcohol treatment sample.

Authors:  Sudan Prasad Neupane; Lars Lien; Priscilla Martinez; Knut Hestad; Jørgen G Bramness
Journal:  Alcohol Clin Exp Res       Date:  2015-01-30       Impact factor: 3.455

Review 5.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

6.  Glia- and tissue-specific changes in the Kynurenine Pathway after treatment of mice with lipopolysaccharide and dexamethasone.

Authors:  Carlos R Dostal; Nicolaus S Gamsby; Marcus A Lawson; Robert H McCusker
Journal:  Brain Behav Immun       Date:  2017-12-11       Impact factor: 7.217

Review 7.  Evidence for a dysregulated immune system in the etiology of psychiatric disorders.

Authors:  Sinead M Gibney; Hemmo A Drexhage
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-05       Impact factor: 4.147

8.  Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.

Authors:  Emil F Coccaro; Royce Lee; Jennifer R Fanning; Dietmar Fuchs; Michel Goiny; Sophie Erhardt; Kyle Christensen; Lena Brundin; Mary Coussons-Read
Journal:  Psychoneuroendocrinology       Date:  2016-05-06       Impact factor: 4.905

Review 9.  Kynurenine pathway metabolites and suicidality.

Authors:  Elena Y Bryleva; Lena Brundin
Journal:  Neuropharmacology       Date:  2016-01-26       Impact factor: 5.250

10.  Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals.

Authors:  Sarah M Clark; Ana Pocivavsek; James D Nicholson; Francesca M Notarangelo; Patricia Langenberg; Robert P McMahon; Joel E Kleinman; Thomas M Hyde; John Stiller; Teodor T Postolache; Robert Schwarcz; Leonardo H Tonelli
Journal:  J Psychiatry Neurosci       Date:  2016-10       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.